Orion has world-class R&D expertise and track-record of developing innovative medicines on its own and with partners into global market. The focus areas of Orion’s R&D are Oncology and Pain, and we are actively looking for new partnering opportunities in these areas.
Early partnerships can take place anywhere from discovery collaboration up to the Phase II. Early partnering may also include partnerships utilizing technology platforms. By combining our R&D and industry expertise with partner capabilities and competences, we can maximize the possibilities of new innovative medicine launches.
Case by case assessment
We have our own scientific scouts looking for opportunities where early partnering can deliver a real benefit for both parties – and ultimately for the patients.
There’s not a ‘one size fits all’ model for early partnerships, but, instead, our experienced teams work diligently to find an early partnering model that is a win- win, tailored and best suited for the given situation.
Committed partner
Orion has decades of experience in partnering with companies of different scale from all over the world. Our expertise covers the whole pharmaceutical value chain, from early R&D, through regulatory processes to excellence in sales and marketing. For start-up companies especially, it is often a tremendous help to team up with a partner with long-term experience and very strong commitment to established partnership.
Collaborating with us
Orion’s External Science and Partnering team in R&D is seeking potential R&D collaborations, including preclinical to early clinical development stage collaborations and in-licensing opportunities in Oncology and Pain.
We are also interested in novel drug discovery technologies and tools for identification of new drug targets.
